Technology in Diabetes Care: From Prevention to Disease Management

Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.

The Future of Diabetes Prevention and Management
June 28, 2017 – 
Experts Robert Gabbay, MD, PhD, FACP; Mary Ann Hodorowicz, RDN, MBA, CDE; Neal Kaufman, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, conclude this panel discussion by calling for better data to drive decisions about technology, and to inform consumers as they play larger roles in healthcare choices.
The Change in the Device Coverage Landscape
June 22, 2017 – 
Robert Gabbay, MD, PhD, FACP; Mary Ann Hodorowicz, RDN, MBA, CDE; Neal Kaufman, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, share their views on the agreement between UnitedHealth and Medtronic, how similar deals could follow, and how value-based payment could be tied not only to glycated hemoglobin levels but also to hypoglycemia.
Evaluating Factors for FDA Approval of Diabetes Devices
June 22, 2017 – 
In this segment, Robert Gabbay, MD, PhD, FACP; Mary Ann Hodorowicz, RDN, MBA, CDE; Neal Kaufman, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, discuss the likelihood that the FDA will improve diabetes care technology more rapidly than it has in the past, as the era of semi-automatic insulin delivery takes hold.
Which Technology Merits Payment in Diabetes Care?
June 09, 2017 – 
Robert Gabbay, MD, PhD, FACP; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, remark that with new and constantly improving technologies on the market, only some have demonstrated evidence in clinical trials that they improve outcomes and reduce costs.
Using Technology to Help Data Make Sense in Diabetes
June 09, 2017 – 
Robert Gabbay, MD, PhD, FACP; Mary Ann Hodorowicz, RDN, MBA, CDE; Neal Kaufman, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, explain that the use of tools in diabetes care requires a partnership between good technology and a patient who is ready and willing to use it, and the next phase will involve technology that gives patients feedback from data at the point of care.
Clinical Rationale for CGM in Diabetes
June 02, 2017 – 
In this segment, Robert Gabbay, MD, PhD, FACP; Mary Ann Hodorowicz, RDN, MBA, CDE; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, discuss the cost of an event of hypoglycemia. The panelists also consider how continuous glucose monitoring (CGM) can reduce the number of events, and explain the FDAs recent decision on CGM dosing with the Dexcom G5.
Diabetes: Role of Payers Versus Role of Technology
June 02, 2017 – 
Robert Gabbay, MD, PhD, FACP; Mary Ann Hodorowicz, RDN, MBA, CDE; Neal Kaufman, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, suggest that technology can help bring the Diabetes Prevention Program to new populations; and smartphones, in particular, can help make diabetes prevention highly accessible.
The Challenges of Diabetes Prevention Programs
May 26, 2017 – 
Robert Gabbay, MD, PhD, FACP; Mary Ann Hodorowicz, RDN, MBA, CDE; Neal Kaufman, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, note that while the cost of the Diabetes Prevention Program in Medicare might seem large, the pilot showed it would be cost-effective in the long run, and many payers have concluded the same thing.
Intervention for Diabetes Prevention
May 25, 2017 – 
Robert Gabbay, MD, PhD, FACP; Mary Ann Hodorowicz, RDN, MBA, CDE; Neal Kaufman, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, discuss foundational evidence for the Diabetes Prevention Program, which led to the YMCA pilot that formed the basis for the program that will soon begin in Medicare.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.